Drug Combination Details
| General Information of the Combination (ID: C77812) | |||||
|---|---|---|---|---|---|
| Name | Vanadium NP Info | + | Carboplatin Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Lung cancer
[ICD-11: 2C25]
|
Investigative | [1] | ||
|
Breast cancer
[ICD-11: 2C60]
|
Investigative | [1] | |||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Biological
Regulation |
Induction | Cell cycle arrest in G0/G1 phase | ||||
| In-vitro Model | A-549 | CVCL_0023 | Lung adenocarcinoma | Homo sapiens | ||
| MDA-231 | Breast cancer | Homo sapiens | ||||
| Experimental
Result(s) |
Combination of vanadium and carboplatin resulted in synergistic antitumor activity in ex vivo cell cultures, and prompted G0/G1 cell cycle arrest and sensitization of tumor cells to carboplatin-induced apoptosis. | |||||
